gla-lsq

Small moleculeexperimental

Clinical trial activity

2 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2016 (NCT02647489)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • gla-lsq

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04177355Phase 1Dec 18, 2019Dynavax Technologies Corporation, Emory University, HIV Vaccine Trials Network, Infectious Disease Research Institute, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington
NCT02647489Phase 1May 1, 2016European Malaria Vaccine Initiative, Expres2ion Biotechnologies APS, Government of France, University of Copenhagen, University of Tuebingen
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Dynavax Technologies CorporationFor profit1012019
Emory UniversityAcademic/Hospital1012019
European Malaria Vaccine InitiativeAcademic/Hospital1012016
Expres2ion Biotechnologies APSFor profit1012016
Government of FranceGovernment1012016
HIV Vaccine Trials NetworkAcademic/Hospital1012019
Infectious Disease Research InstituteAcademic/Hospital1012019
International AIDS Vaccine InitiativeAcademic/Hospital1012019
National Institute of Allergy and Infectious Diseases (NIAID)Government1112019
University of CopenhagenAcademic/Hospital1012016
University of TuebingenAcademic/Hospital1112016
University of WashingtonAcademic/Hospital1012019
12 organizations
Page 1 / 1